Press Release: Biomagnetics Announces LOI to Acquire Lanzhou Sanhuan New Technology-First of Several Acquisitions Targeted at $1.00 BMGP Share Valuation

SAN FRANCISCO-- July 12, 2010 (BUSINESS WIRE)--Biomagnetics Diagnostics Corp., (PINK SHEETS: BMGP) a developer of revolutionary diagnostic systems and technology for HIV, hepatitis, tuberculosis and malaria detection, and other innovative technologies, today announced the signing of a Letter of Intent (LOI) with Lanzhou Sanhuan New Technology Development Ltd. of Ganzu, China. This expected acquisition is the first of several planned acquisitions targeted at a $1.00 share price for Biomagnetics Diagnostics’ common shares. Biomagnetics plans to rapidly transition the trading of its shares to the OTCBB upon the expected completion of its full audit and financial review, which is targeted for release within the next few weeks.

Under the terms of the LOI, Biomagnetics will acquire all assets of Lanzhou, including a unique formulation of PVA film, equipment and patented manufacturing process rights, for which the company’s partners, including the Chinese government, have spent more than ten years and approximately US$40 million developing. The utility patent for “Equipment of Rotary-Drum Production of PVA Film” was issued on April 14, 2008. In addition to the assets of Lanzhou, Biomagnetics will inherit an ongoing Chinese government contract for 600,000 tons annually, upon reaching that production level (gross profit is approximately $1,400 per ton) of PVA film product for a minimum of three years, although additional annual renewals are expected.

PVA, or polyvinyl alcohol film, is a high tensile strength and highly flexible plastic film, with many unique properties. PVA is fully biodegradable, with no toxins or other carcinogens, while dissolving completely in the environment.

Biomagnetics expects this proposed acquisition to be the first of several Chinese technology and product acquisitions targeting a Biomagnetics Diagnostics common share price of $1.00. These acquisitions are expected to result in relatively minor amounts of shareholder dilution that will result in a fully audited and fully reporting company with approximately $125 million in assets and tens of millions of dollars in revenues annually. The Company expects to announce these additional acquisitions over the coming weeks and months. Relative to the acquisition of Lanzhou, Biomagnetics will issue a total of 10 million shares of common stock for the purchase and will agree to capitalize Lanzhou with a minimum capital of $1,000,000 over the next 90 days. Biomagnetics believes this is a highly attractive valuation for current common shareholders, that adds significant value.

“PVA film is in huge demand worldwide in the healthcare, agricultural, meat packing industries. Lanzhou has developed a unique, proprietary and patented process for large scale manufacture. Relative to the market opportunity in the PVA market, the number of shares we are issuing for this acquisition is minimal, commented Clayton Hardman, CEO of Biomagnetics Diagnostics. “Lanzhou is the first of several expected technology acquisitions, all of which we believe will be done at the extremely attractive valuations relative to the overall market opportunity. Our Chinese partners are valuing common shares of Biomagnetics Diagnostics at $1.00 relative to these combined intellectual, product and ongoing contract acquisitions. Simply put, we plan to create tremendous value for the current BMGP shareholder. We continue to believe our common shares are significantly undervalued relative to our strong opportunities in the medical diagnostics arena and very large revenue and profit opportunities relative to these expected Chinese acquisitions.”


About Biomagnetics Diagnostics Corp.

Biomagnetics Diagnostics Corporation is an advanced medical device and biotechnology company. The Company’s revolutionary diagnostic systems, which are based on advanced magnetics, test for any viral or bacterial disease using any body fluid. The Company's technology allows laboratories to perform far more tests in the same amount of time it takes to do a single test. The HTS-MTP platform is designed to detect the actual virus and viral load in body fluids and not just simply screen for the presence of viral antibodies. More information on Biomagnetics Diagnostics Corp. can be seen at

Joe Noel, 925-922-2560
Biomagnetics Diagnostics Corp.